AbbVie (ABBV)
(Delayed Data from NYSE)
$194.29 USD
-1.16 (-0.59%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $193.90 -0.39 (-0.20%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$194.29 USD
-1.16 (-0.59%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $193.90 -0.39 (-0.20%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
Zacks News
AbbVie (ABBV) Outperforms Industry This Year So Far: Here's Why
by Zacks Equity Research
AbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.
Roche's (RHHBY) sBLA For Polivy Combo Accepted by FDA
by Zacks Equity Research
Roche's (RHHBY) sBLA seeking approval for the use of Polivy in combination with R-CHP for previously untreated diffuse large B-cell lymphoma in adults has been accepted in the United States.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Reata (RETA) Q2 Earnings Miss, Revenues Down Y/Y, Stock Down
by Zacks Equity Research
Reata (RETA) reports a wider-than-expected loss in the second quarter of 2022, while revenues miss estimates. Stock falls after updates on pipeline programs.
Ironwood (IRWD) Q2 Earnings Miss, Keeps 2022 Sales Guidance
by Zacks Equity Research
Ironwood (IRWD) miss earnings and revenue estimates in the second quarter. Stock declines.
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
by Zacks Equity Research
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
AbbVie's (ABBV) Q2 Earnings Beat Estimates, Revenues Lag
by Zacks Equity Research
AbbVie's earnings (ABBV) beat estimates for second-quarter 2022, while sales miss the same. ABBV's immunology and neuroscience drugs drive sales. Shares decline in pre-market trading.
AbbVie (ABBV) Q2 Earnings Beat Estimates
by Zacks Equity Research
AbbVie (ABBV) delivered earnings and revenue surprises of 1.81% and 0.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Pfizer (PFE) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of 16.57% and 5.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
AbbVie Q2 Preview: Can Shares Retain Their Strength?
by Derek Lewis
There has been a surplus of buyers for AbbVie shares in 2022, with shares gaining a double-digit 15% and outperforming its Zacks Industry by a fair margin.
AbbVie (ABBV) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
AbbVie's (ABBV) second-quarter results are expected to reflect the impact of strong demand for immunology drugs, aesthetics and cosmetics products. Investors are likely to enquire on ABBV's plans to counter Humira LOE.
Zacks Investment Ideas feature highlights: Coca-Cola, Emerson Electric and AbbVie
by Zacks Equity Research
Coca-Cola, Emerson Electric and AbbVie have been highlighted in this Investment Ideas article.
3 Dividend Kings Suited Perfectly for Income Investors
by Derek Lewis
Meeting the parameters to join the elite Dividend King group speaks volumes about these companies' well-established and thriving nature.
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
The Zacks Analyst Blog Highlights J&J, Novartis, GSK, Merck and AbbVie
by Zacks Equity Research
J&J, Novartis, GSK, Merck and AbbVie are included in this Analyst Blog.
AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pharma Stock Roundup: JNJ, NVS Q2 Earnings, GSK Consumer Unit Spin-Off
by Kinjel Shah
J&J (JNJ) and Novartis (NVS) report Q2 earnings. GSK completes separation of its Consumer Healthcare (CHC) segment.
Zacks Value Investor Highlights: Merck, Maravai LifeSciences, Sensus Healthcare, PetIQ and AbbVie
by Zacks Equity Research
Merck, Maravai LifeSciences, Sensus Healthcare, PetIQ and AbbVie have been highlighted in this Value Investor article.
AbbVie (ABBV) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $147.75, marking a +0.04% move from the previous day.
5 Cheap Healthcare Stocks in 2022
by Tracey Ryniec
Looking for value stocks? Healthcare has been ignored over the last year.
Healthcare ETFs in Focus Ahead of Q2 Earnings
by Sweta Killa
The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio.
Biogen (BIIB) Beats on Q2 Earnings & Sales, Ups 2022 Guidance
by Zacks Equity Research
Biogen (BIIB) beats second-quarter estimates for both earnings and sales. Stock falls despite an increase in the 2022 outlook.
J&J (JNJ) Beats on Q2 Earnings & Sales, Lowers 2022 Guidance
by Zacks Equity Research
J&J (JNJ) beats estimates for second-quarter earnings as well as sales. It cuts the full-year outlook due to currency headwinds.
Johnson & Johnson Has Been Posting Negative Surprises: A Look Under The Hood
by Sejuti Banerjea
JNJ Management expects relatively consistent growth for the rest of the year.